Benzinga | Jul 14, 2021 09:28AM EDT

AcelRx, Aguettant Ink Licensing Agreements For Dzuveo And Two Prefilled Syringe Products

* AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has agreed to provide a license to Laboratoire Aguettant to commercialize Dzuveo in Europe and give AcelRx two prefilled syringe product candidates for the U.S.

* Under the Dzuveo licensing agreement, Aguettant will have the right to commercialize Dzuveo in Europe.

* AcelRx will up to $55 million in a combination of up-front and sales-based milestone payments, along with revenue share payments ranging from 35% to 45% of net sales.

* Under the terms of a separate U.S. licensing agreement, AcelRx obtained the rights to file marketing applications (subject to approval) and commercialize two of Aguettant's EU-approved, prefilled syringe ephedrine and phenylephrine products.

* Aguettant will receive up to $24 million in sales-based milestone payments at various annual sales levels up to $60 million, along with revenue share payments of 40 to 45%.

* Dzuveo is indicated for the management of acute pain in hospital settings.

* Price Action: ACRX shares are up 4.92% at $1.28 during the premarket session on the last check Wednesday.